-+ 0.00%
-+ 0.00%
-+ 0.00%

Amneal agrees to acquire Kashiv BioSciences, deal seen closing in 2026

PUBT·04/22/2026 10:17:26
Listen to the news
Amneal agrees to acquire Kashiv BioSciences, deal seen closing in 2026
  • Amneal agreed to acquire Kashiv BioSciences to build a fully integrated global biosimilars platform.
  • Closing is expected in second half of 2026, subject to Amneal shareholder vote and regulatory clearances.
  • Kashiv brings biosimilar development and manufacturing operations across US and India.
  • Amneal plans to pair Kashiv capabilities with its scale and commercialization footprint to expand biosimilar launches and patient access.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260421283753) on April 22, 2026, and is solely responsible for the information contained therein.